Lornit Sachet contains L-Ornithine L-Aspartate 3gm, an amino acid compound used primarily in the management of hepatic encephalopathy and other liver-related disorders. This formulation acts by enhancing the detoxification of ammonia in the liver, thereby reducing elevated blood ammonia levels commonly associated with liver dysfunction. L-Ornithine L-Aspartate facilitates the urea cycle and glutamine synthesis, promoting the conversion of neurotoxic ammonia into non-toxic urea and glutamine, which are subsequently excreted from the body. It is indicated for patients with acute or chronic liver diseases, including cirrhosis and hepatic encephalopathy, to improve cognitive function and reduce symptoms such as confusion, lethargy, and altered consciousness. Lornit Sachet is administered orally, typically dissolved in water, allowing for convenient dosing and rapid absorption. The safety profile is favorable, with minimal adverse effects reported, although gastrointestinal disturbances such as nausea or diarrhea may occur in some individuals. It is contraindicated in patients with hypersensitivity to any component of the formulation. Lornit Sachet should be used under medical supervision, with dosage adjustments based on clinical response and liver function status. This product provides an effective adjunctive therapy to standard medical management in hepatic encephalopathy and related metabolic conditions.